The China Pharmaceutical Market to 2030
The China Pharmaceutical Market to 2030
Abstract
This new GMR Data report covers the length and breadth of the China Pharmaceutical sector. Every news service globally is focused on COVID-19 (“Coronavirus”) and how it will affect the global population, but what of the China health system itself? How does the sector operate during ’normal’ times?
What will drive and restrain the Chinese health markets?
-Increase in Non-Communicable Disease (NCD)
-Elderly population
-Expanding Middle Class
-Governmental Policy / Trade War
-Industry Harmonization with Global Markets
GMR Data view that the Chinese pharmaceutical sector is set for substantial growth across the next decade as an increasing middle class, which has greater access to healthcare, is set to drive the domestic market significantly. A growing population, which is tilted towards the middle aged and elderly, is another factor that will boost Chinese healthcare and pharmaceutical markets.
China is the largest supplier of raw materials to that produce high-priced, non-generic drugs produced by the US, with an ongoing Trade war Chinese pharmaceuticals face tariffs; this is likely to strengthen the domestic (Chinese) pharmaceutical market in the short to mid-term.
China became a member of the International Council for Harmonization in 2017 and accepted declarations in clinical trials/ approvals by the US FDA and the EMA, shortening clinical trial authorization processes significantly in China.
This GMR Data report is the single tool to equip you with the latest trends in the Chinese pharmaceutical market. This report will arm you with all you and your company require to develop, price, launch and market a product in China, or compete with a Chinese product launched in your market.
With over 100 pages, and over 60+ charts, tables, figures and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.
Content
CHAPTER 1 EXECUTIVE SUMMARY
1.1 REPORT DESCRIPTION
1.2 MARKET SEGMENTATION
1.3 RESEARCH METHODOLOGY
CHAPTER II DRIVERS & RESTRAINTS OF THE CHINESE PHARMACEUTICAL MARKET
CHAPTER III CHINA HEALTHCARE INDICATORS VS GLOBAL HEALTHCARE INDICATORS
3.1 DEMOGRAPHIC INDICATORS
3.2 HEALTHCARE EXPENDITURE
3.3 PRIVATE EQUITY / VENTURE CAPITAL INVESTMENTS
3.4 IMPLICATIONS FROM US - CHINA TRADE WAR ON CHINA PHARMACEUTICAL MARKET
3.4.1. No Impact on Chinese APIs
3.4.2. Adverse Impact on Chinese Outbound Investments, M&As
CHAPTER IV CHINA PHARMACEUTICAL MARKET STRUCTURE
4.1 HEALTHY CHINA 2020 REFORMS - REVIEW
4.2 HEALTHY CHINA 2030 REFORMS – IMPACT ON PHARMACEUTICAL MARKET
4.3 REGULATORY STRUCTURE
4.3.1. Regulatory Authorities
4.3.2. Current Regulatory Policies for Drugs/Pharmaceuticals
4.3.3. Registration Process / Approval for Domestic and Imported Drugs
4.3.4. Intellectual Property Rights / Patent law
4.3.5. Pricing and Reimbursement
4.4 DISTRIBUTION STRUCTURE
4.4.1. Average Sales Force Size
4.4.2. Bribery Penalties - Indications of Changing Pharmaceutical Distribution Practices
4.4.3. China Hospitals Sales, 2020 - 2030 ($ bn)
4.4.4. China Retail Pharmacies Sales, 2020 - 2030 ($ bn)
4.4.5. China e-Pharmacies Sales, 2020 - 2030 ($ bn)
CHAPTER V CHINA PHARMACEUTICAL MARKET
5.1 OVERVIEW
5.2 GROWTH DRIVERS
5.2.1. Higher Proportion of Geriatric Population and Increased Incidence of ‘Lifestyle’ Diseases
5.2.2. Rising Affordability
5.2.3. Supply-Side Reforms Augment Demand
5.3 BARRIERS / RESTRAINTS
5.3.1. Non-Uniform Reimbursements
5.3.2. Low R&D% Investment
5.4 COMPETITIVE LANDSCAPE
5.4.1. Foreign Companies - Key Operating/High ROI Therapeutic Areas
5.4.2. Domestic Companies - Key Operating/High ROI Therapeutic Areas
5.5 TRENDS AND FUTURE OUTLOOK
5.5.1. Massive in-bound funds flow to spur local R&D/innovation
5.5.2. Reverse brain-drain in China pharmaceutical market
5.5.3. Digital customer engagement becoming the necessary evil
CHAPTER VI CHINA PHARMACEUTICAL MARKET, BY TYPE, 2020 - 2030 ($ BN)
6.1 CHINA SMALL MOLECULE DRUGS MARKET, 2020 – 2030 ($ BN)
6.1.1. China Patented Small Molecule Drugs Market, 2020 – 2030 ($ bn)
6.1.2. China Generic Small Molecule Drugs Market, 2020 – 2030 ($ bn)
6.2 CHINA BIOLOGICS MARKET, 2020 – 2030 ($ BN)
6.2.1. China Patented Biologics Market, 2020 – 2030 ($ bn)
6.2.2. China Biosimilars Market, 2020 – 2030 ($ bn)
6.2.3. China Vaccines Market, 2020 – 2030 ($ bn)
CHAPTER VII CHINA APIs MARKET, 2020 - 2030 ($ BN)
CHAPTER VIII CHINA PHARMACEUTICAL MARKET, BY KEY THERAPEUTICS, 2020 - 2030 ($ BN)
8.1 CHINA CARDIOVASCULAR DRUGS MARKET, 2020 – 2030 ($ BN)
8.2 CHINA ANTI-INFECTIVE DRUGS MARKET, 2020 – 2030 ($ BN)
8.3 CHINA ONCOLOGY DRUGS MARKET, 2020 – 2030 ($ BN)
8.4 CHINA DIABETES DRUGS MARKET, 2020 – 2030 ($ BN)
CHAPTER IX COMPANY PROFILES
9.1. SINO BIOPHARMACEUTICAL LTD.
9.1.1. Background
9.1.2. Business Structure - China
9.1.3. Products / Services - China
9.1.4. Distribution Network - China
9.1.5. Growth strategy - China
9.1.6. Financial Information - China
9.2. CSPC PHARMACEUTICAL GROUP LTD.
9.2.1. Background
9.2.2. Business Structure - China
9.2.3. Products / Services - China
9.2.4. Distribution Network - China
9.2.5. Growth strategy - China
9.2.6. Financial Information – China
9.3. ASTRAZENECA CHINA
9.3.1. Background
9.3.2. Business Structure - China
9.3.3. Products / Services - China
9.3.4. Distribution Network - China
9.3.5. Growth strategy - China
9.3.6. Financial Information – China
9.4. PFIZER CHINA
9.4.1. Background
9.4.2. Business Structure - China
9.4.3. Products / Services - China
9.4.4. Distribution Network - China
9.4.5. Growth strategy - China
9.4.6. Financial Information – China
9.5. SHANGHAI PHARMACEUTICALS HOLDING COMPANY LTD.
9.5.1. Background
9.5.2. Business Structure - China
9.5.3. Products / Services - China
9.5.4. Distribution Network - China
9.5.5. Growth strategy - China
9.5.6. Financial Information - China
9.6. FOSUN PHARMA
9.6.1. Background
9.6.2. Business Structure - China
9.6.3. Products / Services - China
9.6.4. Distribution Network - China
9.6.5. Growth strategy - China
9.6.6. Financial Information - China
What will drive and restrain the Chinese health markets?
-Increase in Non-Communicable Disease (NCD)
-Elderly population
-Expanding Middle Class
-Governmental Policy / Trade War
-Industry Harmonization with Global Markets
GMR Data view that the Chinese pharmaceutical sector is set for substantial growth across the next decade as an increasing middle class, which has greater access to healthcare, is set to drive the domestic market significantly. A growing population, which is tilted towards the middle aged and elderly, is another factor that will boost Chinese healthcare and pharmaceutical markets.
China is the largest supplier of raw materials to that produce high-priced, non-generic drugs produced by the US, with an ongoing Trade war Chinese pharmaceuticals face tariffs; this is likely to strengthen the domestic (Chinese) pharmaceutical market in the short to mid-term.
China became a member of the International Council for Harmonization in 2017 and accepted declarations in clinical trials/ approvals by the US FDA and the EMA, shortening clinical trial authorization processes significantly in China.
This GMR Data report is the single tool to equip you with the latest trends in the Chinese pharmaceutical market. This report will arm you with all you and your company require to develop, price, launch and market a product in China, or compete with a Chinese product launched in your market.
With over 100 pages, and over 60+ charts, tables, figures and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.
1.1 REPORT DESCRIPTION
1.2 MARKET SEGMENTATION
1.3 RESEARCH METHODOLOGY
CHAPTER II DRIVERS & RESTRAINTS OF THE CHINESE PHARMACEUTICAL MARKET
CHAPTER III CHINA HEALTHCARE INDICATORS VS GLOBAL HEALTHCARE INDICATORS
3.1 DEMOGRAPHIC INDICATORS
3.2 HEALTHCARE EXPENDITURE
3.3 PRIVATE EQUITY / VENTURE CAPITAL INVESTMENTS
3.4 IMPLICATIONS FROM US - CHINA TRADE WAR ON CHINA PHARMACEUTICAL MARKET
3.4.1. No Impact on Chinese APIs
3.4.2. Adverse Impact on Chinese Outbound Investments, M&As
CHAPTER IV CHINA PHARMACEUTICAL MARKET STRUCTURE
4.1 HEALTHY CHINA 2020 REFORMS - REVIEW
4.2 HEALTHY CHINA 2030 REFORMS – IMPACT ON PHARMACEUTICAL MARKET
4.3 REGULATORY STRUCTURE
4.3.1. Regulatory Authorities
4.3.2. Current Regulatory Policies for Drugs/Pharmaceuticals
4.3.3. Registration Process / Approval for Domestic and Imported Drugs
4.3.4. Intellectual Property Rights / Patent law
4.3.5. Pricing and Reimbursement
4.4 DISTRIBUTION STRUCTURE
4.4.1. Average Sales Force Size
4.4.2. Bribery Penalties - Indications of Changing Pharmaceutical Distribution Practices
4.4.3. China Hospitals Sales, 2020 - 2030 ($ bn)
4.4.4. China Retail Pharmacies Sales, 2020 - 2030 ($ bn)
4.4.5. China e-Pharmacies Sales, 2020 - 2030 ($ bn)
CHAPTER V CHINA PHARMACEUTICAL MARKET
5.1 OVERVIEW
5.2 GROWTH DRIVERS
5.2.1. Higher Proportion of Geriatric Population and Increased Incidence of ‘Lifestyle’ Diseases
5.2.2. Rising Affordability
5.2.3. Supply-Side Reforms Augment Demand
5.3 BARRIERS / RESTRAINTS
5.3.1. Non-Uniform Reimbursements
5.3.2. Low R&D% Investment
5.4 COMPETITIVE LANDSCAPE
5.4.1. Foreign Companies - Key Operating/High ROI Therapeutic Areas
5.4.2. Domestic Companies - Key Operating/High ROI Therapeutic Areas
5.5 TRENDS AND FUTURE OUTLOOK
5.5.1. Massive in-bound funds flow to spur local R&D/innovation
5.5.2. Reverse brain-drain in China pharmaceutical market
5.5.3. Digital customer engagement becoming the necessary evil
CHAPTER VI CHINA PHARMACEUTICAL MARKET, BY TYPE, 2020 - 2030 ($ BN)
6.1 CHINA SMALL MOLECULE DRUGS MARKET, 2020 – 2030 ($ BN)
6.1.1. China Patented Small Molecule Drugs Market, 2020 – 2030 ($ bn)
6.1.2. China Generic Small Molecule Drugs Market, 2020 – 2030 ($ bn)
6.2 CHINA BIOLOGICS MARKET, 2020 – 2030 ($ BN)
6.2.1. China Patented Biologics Market, 2020 – 2030 ($ bn)
6.2.2. China Biosimilars Market, 2020 – 2030 ($ bn)
6.2.3. China Vaccines Market, 2020 – 2030 ($ bn)
CHAPTER VII CHINA APIs MARKET, 2020 - 2030 ($ BN)
CHAPTER VIII CHINA PHARMACEUTICAL MARKET, BY KEY THERAPEUTICS, 2020 - 2030 ($ BN)
8.1 CHINA CARDIOVASCULAR DRUGS MARKET, 2020 – 2030 ($ BN)
8.2 CHINA ANTI-INFECTIVE DRUGS MARKET, 2020 – 2030 ($ BN)
8.3 CHINA ONCOLOGY DRUGS MARKET, 2020 – 2030 ($ BN)
8.4 CHINA DIABETES DRUGS MARKET, 2020 – 2030 ($ BN)
CHAPTER IX COMPANY PROFILES
9.1. SINO BIOPHARMACEUTICAL LTD.
9.1.1. Background
9.1.2. Business Structure - China
9.1.3. Products / Services - China
9.1.4. Distribution Network - China
9.1.5. Growth strategy - China
9.1.6. Financial Information - China
9.2. CSPC PHARMACEUTICAL GROUP LTD.
9.2.1. Background
9.2.2. Business Structure - China
9.2.3. Products / Services - China
9.2.4. Distribution Network - China
9.2.5. Growth strategy - China
9.2.6. Financial Information – China
9.3. ASTRAZENECA CHINA
9.3.1. Background
9.3.2. Business Structure - China
9.3.3. Products / Services - China
9.3.4. Distribution Network - China
9.3.5. Growth strategy - China
9.3.6. Financial Information – China
9.4. PFIZER CHINA
9.4.1. Background
9.4.2. Business Structure - China
9.4.3. Products / Services - China
9.4.4. Distribution Network - China
9.4.5. Growth strategy - China
9.4.6. Financial Information – China
9.5. SHANGHAI PHARMACEUTICALS HOLDING COMPANY LTD.
9.5.1. Background
9.5.2. Business Structure - China
9.5.3. Products / Services - China
9.5.4. Distribution Network - China
9.5.5. Growth strategy - China
9.5.6. Financial Information - China
9.6. FOSUN PHARMA
9.6.1. Background
9.6.2. Business Structure - China
9.6.3. Products / Services - China
9.6.4. Distribution Network - China
9.6.5. Growth strategy - China
9.6.6. Financial Information - China
Related Report
